Citigroup
SPRO icon

Citigroup’s Spero Therapeutics SPRO Stock Holding History

Citigroup’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.8K Buy
19,135
+19,118
+112,459% +$45.4K ﹤0.01% 4565
2025
Q4 		$40 Buy
+17
New +$39 ﹤0.01% 5728
2022
Q4 		– Sell
-495
Closed -$1K – 5944
2022
Q3 		$1K Sell
495
-13,867
-97% -$13.8K ﹤0.01% 5688
2022
Q2 		$11K Buy
14,362
+12,781
+808% +$37.2K ﹤0.01% 5334
2022
Q1 		$14K Sell
1,581
-31,323
-95% -$321K ﹤0.01% 5364
2021
Q4 		$527K Buy
32,904
+16,819
+105% +$267K ﹤0.01% 3749
2021
Q3 		$296K Sell
16,085
-23,245
-59% -$373K ﹤0.01% 3924
2021
Q2 		$549K Sell
39,330
-46,618
-54% -$651K ﹤0.01% 3644
2021
Q1 		$1.26M Buy
85,948
+80,845
+1,584% +$1.42M ﹤0.01% 2808
2020
Q4 		$99K Buy
5,103
+3,483
+215% +$54.3K ﹤0.01% 5544
2020
Q3 		$18K Sell
1,620
-1,356
-46% -$16K ﹤0.01% 6279
2020
Q2 		$40K Sell
2,976
-1,066
-26% -$12K ﹤0.01% 6159
2020
Q1 		$33K Buy
4,042
+1,644
+69% +$14.5K ﹤0.01% 6352
2019
Q4 		$23K Buy
2,398
+1,108
+86% +$11.9K ﹤0.01% 6875
2019
Q3 		$14K Sell
1,290
-1,339
-51% -$14.1K ﹤0.01% 6926
2019
Q2 		$31K Buy
2,629
+625
+31% +$7.52K ﹤0.01% 6848
2019
Q1 		$25K Sell
2,004
-256
-11% -$2.72K ﹤0.01% 6840
2018
Q4 		$14K Sell
2,260
-73
-3% -$591 ﹤0.01% 7043
2018
Q3 		$24K Buy
2,333
+1,018
+77% +$11.8K ﹤0.01% 7001
2018
Q2 		$19K Buy
1,315
+513
+64% +$6.56K ﹤0.01% 6949
2018
Q1 		$11K Buy
802
+121
+18% +$1.47K ﹤0.01% 7021
2017
Q4 		$8K Buy
+681
New +$8.36K ﹤0.01% 7116

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's SPRO Position: Q1 2026 in Review

Citigroup increased its Spero Therapeutics (SPRO) stake by 112,459% in Q1 2026, buying an estimated $45.4K and bringing the position to 19,135 shares worth $44.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4565.

Citigroup first reported a position in SPRO in Q4 2017 and has held it in 22 quarters since. The position peaked at $1.26M in Q1 2021. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Citigroup held 19,135 shares of Spero Therapeutics worth $44.8K as of Q1 2026.
  • Citigroup bought 19,118 Spero Therapeutics shares in Q1 2026, an estimated $45.4K.
  • Spero Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4565 holding.
  • Citigroup first reported a position in Spero Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • Citigroup's Spero Therapeutics position peaked at $1.26M in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.